Georgetown University ranks second among the nation’s colleges and universities in graduating women who go on to lead venture capital firms, according to a report published by the investment company Different Funds.
Image: https://thehoya.com
Richmond, VA., February 22, 2021 – Phlow Corp., a public benefit essential medicines solutions provider, and the United States Pharmacopeia (USP) today announced a strategic alliance to develop a new laboratory that will certify and validate Pharmaceutical Continuous Manufacturing processes resulting in affordable, high-quality, U.S.-manufactured essential medicines. Throughout its 200-year history of setting standards for medicine quality, USP has been providing validated scientific methods used by manufacturers and regulators to determine what “good quality” looks like. The methods developed through this strategic alliance will be available for use by other domestic generics manufacturers to encourage broader adoption of Pharmaceutical Continuous Manufacturing in order to strengthen the U.S. drug supply.
USP, a global, scientific not-for-profit organization located in Rockville, Maryland, develops public standards that establish the quality expectations for medicines, collaborating with scientific experts from the academic, industry, and healthcare practitioner communities along with the U.S. FDA. The alliance will facilitate Phlow’s application of “flow” chemistry and other continuous advanced manufacturing processes to produce the crucial ingredients that enable domestic, end-to-end drug manufacturing of essential medicines that have been or are at risk of being in shortage thereby contributing to a more resilient medicines supply chain.
VIRTUAL SBIR and OTHER NON-DILUTIVE FUNDING SOURCES WORKSHOP with 1:1 PARTNERING – March 17-18, 2021
Don’t miss a unique opportunity to discuss your biohealth technology innovation directly with Program Officers from NSF, various institutes at NIH (including NIA, NCI, NIDA, and NHLBI), the University of Maryland MIPS program. Learn the latest about the current areas of focus for these funding resources, Tips and Tricks for submitting successful applications, and Additional Resources to support your early stage company. Confirmed speakers and partnering meeting participants include:
- Stephanie Davis, PhD – Small Business Program Coordinator, NIH National Heart Lung and Blood Institute (NHLBI)
- Stephanie Fertig, HHS Small Business Program Lead, National Institutes of Health (NIH)
- Armineh Ghazarian – Program Analyst, NIH National Institute of Aging
- Colleen Gibney, SBIR Deputy Project Manager, USAMRDC
- Henry Ahn – Program Director, National Science Foundation (NSF)
- Todd Haim, PhD – Chief, Office of Small Business Research, NIH National Institute of Aging
- Elena Koustova, PhD, MBA – Director, Office of Translational Initiatives and Program Innovations (OTIPI), NIDA SBIR/STTR Coordinator, NIH National Institute of Drug Abuse (NIDA) Office of Director
- JR Meyers, SBIR Project Manager, USAMRDC
- Victor Prikhodko – Senior Business Dev. Manager, SBIR/STTR NIH National Institute of Drug Abuse (NIDA)
- Saroj Regmi, PhD – Health Science Administrator Office of Small Business Research, NIH National Institute of Aging
- Andrea Renner – SBIR Deputy Project Manager, USAMRDC
- Ben Schrag, PhD – Program Director, National Science Foundation (NSF)
- Onur Unal, Manager, Life Sciences Projects, Maryland Industrial Partnerships (MIPS), Maryland Technology Enterprise Institute (Mtech), University of Maryland
Additional participants from the NIH National Cancer Institute and other resources TBA.
Click here to.. Reserve your spot (no fee) today!
Don’t miss a unique opportunity to discuss your biohealth technology innovation directly with Program Officers from NSF, various institutes at NIH, the University of Maryland MIPS program, and others. Learn the latest about the current areas of focus for nondilutive funding resources, tips for submitting successful applications, and additional resources to support your early-stage company. Confirmed speakers and partnering meeting participants include:
- Henry Ahn – Program Director, National Science Foundation (NSF)
- Lynne Stein Benzion – Director, Economic Development, Montgomery County Econ. Dev. Corp. (MCEDC)
- Katie Bratlie – Program Director, National Science Foundation (NSF)
- Christie Canaria, PhD – Program Director, SBIR Development Center, National Cancer Institute (NCI)
- Judy Costello – Managing Director, Economic Development, BioHealth Innovation (BHI)
- Stephanie Davis, PhD – Small Business Program Coordinator, NIH Nat’l Heart Lung & Blood Inst. (NHLBI)
- Sharon Disque, Economic Development Manager, City of Gaithersburg, Maryland
- Stephanie Fertig, HHS Small Business Program Lead, National Institutes of Health (NIH)
- Jonathan Franca-Koh, PhD – Program Director, SBIR Development Center, National Cancer Inst (NCI).
- Armineh Ghazarian – Program Analyst, NIH National Institute of Aging (NIA)
- Colleen Gibney, SBIR Deputy Project Manager, USAMRMC (DoD)
- Todd Haim, PhD – Chief, Office of Small Business Research, NIH National Institute of Aging (NIA)
- Elena Koustova, PhD, MBA – Director, Office of Translational Initiatives and Program Innovations (OTIPI), NIDA SBIR/STTR Coordinator, NIH National Institute of Drug Abuse (NIDA) Office of Director
- Ashwin Kulkarni, COO, miRecule; Associate, BioHealth Innovation, Inc. (BHI)
- Carla Merritt, Senior Business Development Representative, Maryland Department of Commerce
- JR Meyers, SBIR Project Manager, USAMRMC (DoD)
- Alastair Monk – Program Director, National Science Foundation (NSF)
- Deepa Narayanan – Program Director and Team Lead, NIH National Cancer Institute SBIR Development Center (NCI)
- Rini Pek PhD – Senior Analyst, BioHealth Innovation, Inc. (BHI)
- Erik Pierstorff – Program Director, National Science Foundation (NSF)
- Victor Prikhodko – Senior Business Dev. Mgr., SBIR/STTR NIH National Inst. of Drug Abuse (NIDA)
- Monique Pond, PhD – Program Director, SBIR Development Center, National Cancer Institute
- Reema Railkar, PhD – Program Manager, SBIR Development Center, National Cancer Institute
- Saroj Regmi, PhD – Health Science Administrator, Office of Small Business Research, NIH National Institute of Aging
- Andrea Renner – SBIR Deputy Project Manager, USAMRMC (DoD)
- Ethel Rubin, PhD – Entrepreneur-in-Residence, BioHealth Innovation, Inc. (BHI)
- Anthony Saleh, PhD – CEO, miRecule
- Ben Schrag, PhD – Program Director, National Science Foundation (NSF)
- John Sullivan – Entrepreneur-in-Residence, BioHealth Innovation, Inc. (BHI)
- Onur Unal, Manager, Life Sciences Projects, Maryland Industrial Partnerships (MIPS), Maryland Technology Enterprise Institute (MTech), University of Maryland
Register (no fee) today! www.tinyurl.com/2021SBIR
for The Rockville-based National Foundation for Cancer Research is accepting applications through Sunday evening, February 28, from academic laboratory and early stage start-up-based promising oncology technology projects for its 2021 Salisbury Award Competition for Entrepreneurial Translational Research. In addition to increased exposure, insight from a world-class judging panel and access to NFCR’s network, cash prizes totaling $10,000 will be provided to three category winners, the first one of which who will also be introduced to the AIM-HI Accelerator Fund for consideration of investment. Learn more and apply here: https://www.nfcr.org/salisbury-award/.
The National Foundation for Cancer Research is proud to present the Salisbury Award in honor of the Salisbury family’s vision and legacy of funding “high risk, high impact, and high reward” cancer research. Over 80 years of service, the three Salisburys galvanized NFCR into a significant force in cancer research worldwide.
The Salisbury Award encourages and promotes innovative scientists and early stage startups to translate their discoveries into therapies that can improve the lives of cancer patients. The initiative is designed to catalyze and advance promising research innovations onto the path of commercialization. Download the flyer and help spread the word!
Gaithersburg, MD, Feb. 22, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering mRNA-engineered cell therapy in and beyond oncology, today announced that it has initiated a Phase 2a clinical trial of its mRNA chimeric antigen receptor (CAR) T-cell therapy, Descartes-11, in patients with newly diagnosed, high-risk multiple myeloma. Based upon the company’s research and analysis, this program is understood to be the first RNA-engineered cell therapy to enter clinical development for a frontline cancer. Descartes-11 is the third product candidate to be evaluated in clinical trials resulting from Cartesian’s RNA Armory℠ engineering platform.
GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s COVID-19 vaccine. Novavax has previously reported positive interim efficacy results of NVX-CoV2373, its recombinant protein-based vaccine candidate, in an ongoing Phase 3 clinical trial taking place in the United Kingdom.
The LaunchPort™ announced today that Eyedea Medical (https://www.eyedeamedical.com/) joined the Venture Center and will make the Port Covington, Baltimore location their HQ and engineering site.
Eyedea Medical is an early-stage, ophthalmic medical device company that was spun out of the Wilmer Eye Institute and the Center for Bioengineering Innovation & Design at Johns Hopkins University. Eyedea Medical was formed by a group of ophthalmologists and biomedical engineers in 2019 to alleviate the burden of corneal blindness globally through development and commercialization of a series of devices with potential to improve outcomes and access to vision-restoring corneal procedures.
Deka BioSciences CEO, John Mumm, CEO of Deka BioSciences, virtually guests on BioTalk to discuss his history in the BioHealth Capital Region, Precision Medicine, and Funding Strategies.
Listen now via Apple http://apple.co/3aIy6Ew, Google http://bit.ly/3sfEysd, Spotify http://spoti.fi/3aJq8ei, and Tunein http://bit.ly/2Me25ut.